2Kelly PJ, Archbold P, Price JH, et al. Serum CA19-9 levels are commonly elevated in primary ovarian mucinous turnouts but cannot be used to predict the histological subtype [J]. J Clin Pathol, 2010, 63:169-173.
3Tamakoshi K, Kikkawa F, Shibata K, et al. Clinical value of CA125, CA199, CEA, CA72-4, and TPA in borderline ovarian tumor[J]. Gynecol Oncol, 1996, 62:67-72.
4Coumbos A, Sehouli J, Chekerov R, et al. Current management of borderline ovarian tumors: A multieenter survey of 323 clinics in Germany, on behalf of the North-Eastern German Society of Gynecological Oncology (NOGGO) [J]. Br J Cancer, 2009, 100 (11): 1731-1738.
5Hart WR. Borderline epithelial tumors of the ovary[J]. Mod Pathol, 2005,18: S33-S50.
6Gultekin E, Gultekin OE, Cingillioglu B, et al, The value of frozen section evaluation in the management of borderline ovarian tumors[J]. J Cancer Res Ther,2011,7(4):416-420.
7Ren JPZ, Yang K. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors[J]. Gynecologic Oncology,2008,110 (2): 162-167.
8Tsai HW, Twu NF, Yeh CC, et al. Unilateral salpingooophorectomy as fertility-sparing surgery for borderline ovarian tumors[J]. J Chin Med Assoc ,2011,74:250-254.
9Lenhard MS, Mitterer S, Kumper C, et al. Long-term follow-up after ovarian borderline tumor: Relapse and survival in a large patient cohort[J]. Eur J Obstet Gynecol Reprod Biol, 2009,145 : 189-194.
10DeIaco P, Ferrero A, Rosati F, et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery[J]. Eur J Surg Oncol, 2009, 35(6): 643-648.
